BRAF, MEK Inhibition Shows Strong Long-Term Survival Benefit in Melanoma

June 22, 2016

In this video we discuss 3-year results of the COMBI-d trial, which studied dabrafenib and trametinib in patients with unresectable or metastatic BRAF-mutated melanoma.

Updated survival data of the COMBI-d trial, which studied dabrafenib and trametinib in patients with unresectable or metastatic BRAF-mutated melanoma, as well as analyses aimed at understanding patients who best responded to treatment were presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held earlier this month in Chicago (abstract 9502).

In this video, Caroline Robert, MD, PhD, of the Institut Gustave Roussy in Paris, discusses these new findings.